Company news

Cullinan Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

November 6, 2024

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

November 4, 2024

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

November 3, 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

October 15, 2024

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

September 16, 2024

Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

September 15, 2024

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

September 13, 2024

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

August 7, 2024

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

May 31, 2024

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

May 23, 2024

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

May 22, 2024

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 14, 2024

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

April 28, 2024

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

April 23, 2024

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

April 15, 2024

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

April 15, 2024

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 13, 2024

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

February 29, 2024

Cullinan Oncology to Participate in Upcoming Investor Conferences

February 26, 2024

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 17, 2023

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

December 13, 2023

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 7, 2023

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

November 2, 2023

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 9, 2023

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

August 8, 2023

REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

August 2, 2023

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

May 24, 2023

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 10, 2023

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

April 25, 2023

Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

April 19, 2023

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

March 26, 2023

Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

March 13, 2023

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

March 8, 2023

Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference

February 26, 2023

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

February 12, 2023

Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference

February 1, 2023

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 31, 2023

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

January 23, 2023

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 13, 2022

Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

November 1, 2022

Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619

October 24, 2022

Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference

September 6, 2022

Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer

August 14, 2022

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 9, 2022

Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference

July 31, 2022

Cullinan Oncology to Participate in William Blair Biotech Focus Conference

July 4, 2022

Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417

June 22, 2022

Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

May 30, 2022

Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting

May 25, 2022

Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference

May 18, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 17 decks. Every deck is listed under its year.